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Abstract In order to achieve higher dosages than previ-
ously used in clinical trials, we conducted a phase I trial to
determine the maximum tolerated dose (MTD) for the
combination of erlotinib and sirolimus for the treatments of
recurrent malignant gliomas. Patients with pathologically
proven World Health Organization (WHO) grade III glioma
and grade IV glioblastoma and radiographically proven
tumor recurrence were eligible for this study. Treatments
included once daily erlotinib, which was given alone for the
first 7 days of treatments, then in combination with once
daily sirolimus. Sirolimus was given with a loading dose on
day 8 followed by a maintenance dose starting on day 9.
Dose-limiting toxicity (DLT) was determined over the first
28 days of treatments, and the MTD was determined in a
3 ? 3 classic study design. 19 patients were enrolled, and 13
patients were eligible for MTD determination. The MTD was
determined to be 150 mg daily for erlotinib and 5 mg daily
(after a 15 mg loading dose) for sirolimus. The DLTs
included rash and mucositis (despite maximal medical
managements), hypophosphatemia, altered mental status,
and neutropenia. The combination of erlotinib and sirolimus
is difficult to tolerate at dosages higher than previously
reported in phase II trials.
Keywords Erlotinib  Sirolimus  Recurrent gliomas 
Combination study
Introduction
The incidence of primary malignant brain and central
nervous system tumors in the United States is about 22,000
per year. These tumors cause over 13,000 deaths per year
[1]. Of all malignant primary brain and central nervous
system tumors, gliomas are the most common, with more
than half of the cases comprising of malignant gliomas
(World Health Organization, WHO grade III and IV).
Despite optimal treatment with surgery, radiation therapy
and chemotherapy, the prognosis remains poor. In the most
aggressive type, grade IV glioblastoma (GBM), almost
90 % of patients will have tumor progression by 2 years
after the standard treatments of radiation therapy combined
with temozolomide chemotherapy [2]. At recurrence,
treatments with alkylating chemotherapies or biological
agents result only in a 6 months progression free survival
(PFS) of 28–31 % for patients with WHO grade III and
15–16 % for those with grade IV [3, 4], and slightly longer
at 29–45 % for those with grade IV treated with bev-
acizumab [5, 6]. Thus, more effective treatments at recur-
rence still need to be defined.
Targeting molecular aberrant pathways have been one
option to enhance treatments against malignant gliomas,
including inhibition of the epidermal growth factor receptor
(EGFR). EGFR is activated by the ligand EGF which in turn
activates multiple cell signaling pathways and modulates
tumor cell division, invasion and apoptosis [7]. In addition,
EGFR activation also indirectly affects factors that play an
important role in tumor cell survival and growth such as
vascular endothelial growth factor directed angiogenesis [8].
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Dysregulation of EGFR via overexpression, amplification,
and mutation affects the majority of malignant gliomas
[9–11]. Two different types of mutations to the EGFR gene
in GBM have been discovered. One mutation with deletion
of several exons in the gene, EGFRvIII, leads to constitutive
activation of the receptor. Several other missense mutations
in the extracellular domain also lead to increased activation
of the receptor [12]. Recently, The Cancer Genome Atlas
project confirmed that about 45 % of GBM tumors harbor
either focal amplification, mutation, or both of the EGFR
gene[13], confirming that EGFR is a critical mediator of
GBM pathogenesis and therefore represents a potentially
important therapeutic target.
There have been several trials of EGFR inhibitors in
GBM, mainly using small molecular ATP-competitive
tyrosine kinase inhibitors Several phase II trials of EGFR
inhibitors such as erlotinib or gefitinib have demonstrated
limited effectiveness of these agents for gliomas[14].
Looking at tumor response to erlotinib or gefitinib, Mel-
linghoff et al. [15] found that EGFRvIII sensitize tumors to
EGFR kinase inhibitors, and loss of the phosphotase tensin
homologue of ten (PTEN) tumor suppressor would impair
the response to such inhibitors. In tumor tissues of subjects
given erlotinib or gefitinib for the treatment of recurrent
GBM, EGFRvIII/PTEN protein coexpression was signifi-
cantly associated with clinical response. The constitutively
active mutant EGFRvIII is known to strongly and persis-
tently activate the phosphatidylinositol 30 kinase (PI3K)
signaling pathway, which provides critical information for
cell survival, proliferation, and motility. The loss of PTEN,
which can be seen in 36 % of glioblastoma [13], may pro-
mote cellular resistance to EGFR kinase inhibitor therapy by
dissociating EGFR inhibition from downstream PI3K path-
way inhibition. Treatments targeting the PI3K pathway
using mTOR-C1 inhibitors, the rapalogues, have not been
successful as monotherapy for recurrent GBM, either, and
may lead to increase activation via loss of negative feedback
and reactivation of the pathway via AKT [16].
Since monotherapy with either EGFR inhibitors or
rapalogues does not provide tumor control, a rational
approach to overcome the resistance to EGFR inhibitors in
tumors with PTEN loss might include combining treat-
ments with both an EGFR inhibitor and an inhibitor of the
PI3K pathway for synergistic therapeutic success [17]. An
early pilot study found that the combination of a receptor
tyrosine kinase inhibitor such as gefitinib or erlotinib with
the mTOR inhibitor sirolimus can lead to tumor response
[18]. However, a subsequent phase II study of erlotinib and
sirolimus that utilized standard, single-agent doses of each
agent, was conducted in 32 patients with recurrent GBM,
but no response was seen with this combination [19].
In previous monotherapy trials, the doses of erlotinib
have ranged from 150 to 200 mg for patients not on
enzyme-inducing seizure medications [15, 20]. Our phase I
trial of the mTOR inhibitor rapamycin was able to reach a
daily dose of 10 mg [16]. Previous studies of erlotinib and
sirolimus, however, used lower dosages of these drugs,
usually 150 mg for erlotinib and 4–5 mg daily of erlotinib
without seeing any significant toxicities and infrequent
grade III or greater events [18, 19]. Therefore, we con-
ducted a phase I trial of erlotinib in combination with si-
rolimus to determine the feasibility of escalating the doses
in this combination to the maximum dosages seen in
monotherapy. This manuscript reports the results and
maximum tolerated dose (MTD) of this combination in
patients with recurrent malignant glioma.
Patients and methods
Patient population
Eligible patients were C18 years of age with recurrent
malignant gliomas (pathologically confirmed WHO grade
III or IV). Patients must have unequivocal radiographic
evidence of disease recurrence by Macdonald criteria and
evaluable or measureable disease on either magnetic reso-
nance imaging (MRI) or computed tomography (CT). There
were no restrictions on the number of previous recurrences
and treatments, but patients must have failed treatment with
radiation therapy. Eligibility criteria also included KPS C60
and adequate hematologic and organ function. Patients were
excluded if they received previous treatments with EGFR-
inhibitors or mTOR inhibitors, were receiving enzyme-
inducing antiepileptic drugs, were diagnosed with psychi-
atric disorders, or were pregnant or breastfeeding. The pro-
tocol and informed consent were approved by the University
of California at Los Angeles (UCLA) Institutional Review
Board. All patients reviewed, signed, and provided written
informed consent before enrollment.
Study design
This study was a phase I dose-escalation trial to establish
the MTD of the combination of erlotinib and sirolimus.
The study was also designed to define the safety profile of
this combination.
Dosing and escalation
Erlotinib (Tarceva) was supplied by Genentech, Inc.;
South San Francisco, CA; and was given once a day in
combinations of 25, 100, and 150 mg tablets. Patients were
instructed to take these tablets in the morning with up to
200 ml of water 1 h before and 2 h after food. Erlotinib was
started on Cycle one day 1 of the study.
J Neurooncol
123
Sirolimus (rapamycin: Rapamune: Wyeth-Ayerst, PA,
USA) is commercially available in 1 mg tablets. In order to
establish pharmacokinetic data and toxicities related to
erlotinib alone, sirolimus was not started until day 8 of cycle
one with a loading dose, usually three times the daily main-
tenance dose. Starting day 9, sirolimus was given at a once
daily maintenance dosage. This study drug also needed to be
taken on an empty stomach with avoidance of grapefruit juice.
Dosages of erlotinib and sirolimus for each dose level
were given according to the Dose escalation scheme
(Table 2). Dose escalation was performed in cohorts of
three patients beginning at a starting dose of erlotinib of
150 mg per day and maintenance sirolimus of 5 mg per
day (loading dose of 15 mg) (Dose Level 1). If no dose-
limiting toxicity (DLT) occurred in that cohort, a sub-
sequent cohort of three additional patients opened at the
next dose level. If one patient experienced a DLT, three
more patients were added to that dose cohort. The MTD
was defined as the dose at which no more than one in six
patients experienced a DLT and at which the next higher
dose exceeded that limit, or the maximum planned dose
level. Patients had to complete at least 21 days of the
combination of treatments or experienced DLT within the
first cycle of treatment to be evaluable for safety and DLT.
A cycle of treatment was defined as 28 days starting on the
first day of erlotinib.
In the first version of our protocol, the maximum dose
level allowed for titration (dose level 3) was erlotinib
200 mg and sirolimus daily dose of 7.5 mg, based on single
agent MTDs for these two drugs. Dose level 3 would have
been achieved by dose escalation for erlotinib first (level
2), followed by dose escalation for sirolimus (level 3) if no
DLTs at Dose Level 2. However, we later amended the
protocol to try dose escalation of sirolimus only (Dose
Level 2b) when dose level 2 had more than two DLTs.
Patient evaluation
Pretreatment evaluation included a medical history and
physical examination. Baseline tumor measurements by
MRI or CT and baseline laboratory studies for hematology
and chemistry were obtained within 14 days before study
entry. Baseline EKG, Chest X-ray, and fasting lipid levels
were also obtained during this time. Hematology, chemis-
try, and cholesterol panels were repeated every 4 weeks
along with a complete physical and neurological exami-
nation for the first two cycles, then subsequently every
other cycle. MRI/CT was performed every 4 weeks for the
first two cycles then every 8 weeks for subsequent cycles.
Patients with stable or responding disease continued the
combination of erlotinib and sirolimus at the same dose
level unless a DLT occurred in which case they received a
reduced dose at the next cycle.
DLT was evaluated according to the National cancer
institute common toxicity criteria ver. 3. DLT was defined
as any grade IV hematologic toxicity, any nonhematologic
grade III toxicity (except for diarrhea or rash at grade III
that were not maximally medically treated), and failure to
recover from toxicities within 3 weeks from the last dose
of study drug. The toxicities of rash and diarrhea were
considered DLTs only if they remained at grade III or
greater despite maximal medical treatments and required
more than 21 days of dose interruption or dose reduction.
Patients were eligible for DLT determination only if they
have taken study drugs for more than 21 days or had a
grade III or higher toxicity attributable to study drugs.
Sirolimus trough levels were obtained 3 weeks after the
start of sirolimus dosing, on day 28 of cycle one, and at the
end of subsequent cycles. The levels were evaluated by the
UCLA clinical laboratories. We were unable to evaluate
serum levels for erlotinib.
Tumor progression was defined as a new enhancing
lesion representing tumor greater than 1 cm2 in size, tumor
growth of [25 % of the enhancing tumor at stable steroid
dosage, failure to return for evaluation due to death, or
deteriorating neurological condition.
Statistical considerations
The primary end points for this phase I study of erlotinib
and sirolimus were to define DLT and determine the MTD
for dosing in a phase II trial. The dose for patients was
escalated as described, and DLT, MTD, and safety were
evaluated. A classical 003 ? 300 study design was used to
determine the MTD, where the MTD is defined as the dose
level at which no more than 1/6 patients experienced a
DLT, and two or more patients experienced a DLT at the
next higher dose level. The DLT-evaluation period was the
first 28 days of treatments. A patient was replaced if the
patient was not evaluable for toxicity for at least 28 days of
treatments and did not experience a DLT within the first
cycle of treatment.
This phase I study also had an exploratory secondary




A total of 19 patients were enrolled between December
2007 and June 2010 (Table 1). All patients failed treat-
ments with both radiotherapy and temozolomide chemo-
therapy. Most of the patients (14 / 19) had GBM and were
treated in the 1st or 2nd recurrence. Patients were enrolled
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in three different dose levels in cohorts of 3, with
replacement if a patient did not meet criteria for safety
evaluations for DLT as defined above (Table 2).
Toxicity
In the DLT evaluation period, there was one grade III
neutropenia in the first cohort. At this level, three subjects
subsequently withdrew consents to continue study prior to
completing the DLT evaluation period. One subject was
unwilling to continue follow-up due to distance, and two
other subjects had grade II but intolerable side effects did
not want to continue with the trial. The remaining two
subjects did not experience any DLT. Upon dose escalation
to level 2, two subjects developed DLTs with prolonged
grade III mucositis (1) and grade III rash (1), despite
maximal medical managements. At this point, the protocol
was amended to titrate up sirolimus instead of erlotinib
(dose 2b). However, two more subjects had DLTs at this
level with one grade III hypophosphatemia and one Serious
Adverse Events with hospitalization for altered mental
status, without tumor progression, in the DLT evaluation
period. At this level, one subject also withdrew consent
prior to completing the first cycle. As a result, dose level 1
was expanded to another three patients (with two subjects
withdrawing consent before evaluable for DLTs) and had
no further DLTs. Therefore, the MTD was determined to
be dose level 1 (Table 2).
The most frequent toxicities attributable to erlotinib and/
or sirolimus, including those occurring outside of the DLT
period and in more than 20 % of subjects, are listed in
Table 3. In summary, most of the toxicities were expected
side effects. Rash was the most frequent toxicity which
occurred in almost all (17 / 19) patients, usually within
1 week of treatment with erlotinib. Most of the rash side
effects were grade I and II, although there were four events
with grade III rash. Rash was easily managed with topical
corticosteroids and oral minocycline in most cases and
usually dissipated within a few days of initiating
treatments.
Mucositis was another frequent adverse event after
about 1–2 weeks on combination therapy, mostly at grade
I–II, but one subject did have grade III mucositis despite
maximal medical interventions leading to a DLT. Other
frequent grade III non-hematological toxicities, occurring
outside of the DLT-evaluation period, included diarrhea,
fatigue, dry skin, and wound breakdown. Rare grade III
events were seen with anorexia, headache, nausea, and
deep venous thrombosis. One subject did experience grade
IV toxicity with pulmonary embolism, and one patient had
an asymptomatic intraparenchymal hemorrhage inciden-
tally detected on imaging.
The most frequent hematological toxicity was throm-
bocytopenia, with one grade III thrombocytopenia. There
were several patients with grade III leukopenia and one
with grade III neutropenia. None of the subjects developed
severe hyperglycemia, and one subject developed grade III
hypercholesterolemia.
Pharmacokinetic data
Sirolimus trough levels for patients evaluable for DLT are
listed in Table 4. Overall, the dose levels were variable in
the different cohorts. Although the highest drug level was
seen in Cohort 2b, the serum level does not correlate with
the degree of toxicity (data not shown).
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1 150 15/5 11 1 5 6
2 200 15/5 3 2 0 3




Although survival was not the primary objective of this
phase I study, we did follow patients for median PFS. None
of the patients remained on study beyond 6 months. The
median PFS was 28 days on this treatment for all dose
levels. The best tumor response was stable disease, and no
objective response was seen with the combination of
treatment.
Discussion
In conclusion, this phase I study of the combination of
sirolimus and erlotinib found the MTD for this combina-
tion to be erlotinib of 150 mg per day and sirolimus of
5 mg per day. These dosages are lower than dose levels
reached by prior studies of single agent erlotinib or sirol-
imus [16, 20] and definitely not an improvement in the
previous phase II trial of this combination [19]. Since we
were unable to achieve higher dosages than previous
unsuccessful clinical trials of erlotinib and/or sirolimus,
therefore, we terminated the trial and did not proceed with
the phase II trial of this combination.
Given that malignant gliomas can have multiple aberrant
molecular targets, combination targeted therapies likely have
more efficacy than single agent therapies [17]. Single agent
molecular targeted trials in recurrent glioblastoma have
shown little improvement in survival [21]. However, multiple
combination therapies, including those targeting EGFR
pathway and/or PI3K pathway still did not show an
improvement in survival over single agents [14] Furthermore,
from the experience of this phase I trial, combination therapies
can also be limited by increased toxicities due to overlapping
target inhibitions at higher than minimal dosages.
Our subjects experienced toxicities well-known in the
side effect profiles of both drugs, including rash and diarrhea
for erlotinib, and mucositis for sirolimus, increasing the
frequency of DLTs. The combination also seems to have
higher frequencies of fatigue, altered mental status, and
mucositis than expected with single agents. Many subjects
also withdrew consents before even developing any DLTs,
Table 3 Toxicities
*DLTs
# only one event leading to
DLT despite maximal medical
management
Adverse Event Description Grade I Grade II Grade III Grade IV Total Number of subjects
Diarrhea 12 3 5 0 19 14
Nausea 3 4 1 0 8 6
Rash 16 12 4*# 0 31 17
Dehydration 0 5 4 0 0 8
Fatigue 2 10 3 0 13 11
Stomatitis/mucositis 5 6 3*# 0 13 10
Anorexia 4 1 2 0 6 8
Hypercholesterolemia 1 3 2 0 5 6
Hypophosphatemia 0 1 1* 0 2 1
Dry skin 3 1 2 0 6 5
Skin breakdown/wound 1 3 2 0 6 4
Leukopenia 1 3 4 0 8 3
Neutropenia 1 2 1* 0 4 3
Thrombocytopenia 12 3 1 0 16 11
Headache 1 3 1 0 5 4
Altered mental status 1 1 1* 0 3 3
Photosensitivity 3 0 1 0 2 3
Confusion 1 0 1 0 2 2
Deep Venous Thrombosis 0 0 1 0 1 1
Pulmonary Embolism 0 0 0 1 1 1
CNS bleed 0 0 1 0 1 1
Table 4 Sirolimus Levels
Sirolimus mean levels were













1 150 15/5 13.0 9.4–21.6
2 200 15/5 10.0 7.2–12.8
2b 150 30/10 22.9 13.6–35.2
J Neurooncol
123
suggesting subjective intolerability to this combination.
Other combinatorial studies for treatments of GBM have also
resulted in increased toxicities when combining agents
without improved efficacy, possibly from pharmacokinetic
interactions between the two drugs [22, 23]. Serum levels for
sirolimus did not seem to correlate with the degree of tox-
icity. Unfortunately, our current study could not determine
the potential pharmacokinetic interactions between the two
therapies since we were unable to evaluate drug levels for
erlotinib. However, the sirolimus levels at each dose cohort
were similar to the range seen in our previous phase I study of
sirolimus alone [16], suggesting that the addition of erlotinib
did not significantly alter the pharmacokinetic of sirolimus.
Future clinical studies on molecular treatments should
consider other strategies to achieve better target inhibition
without additional toxicity. Choice of agents for combi-
nation treatments should be based on both logical molec-
ular targets and complimentary side effect profiles. Another
option includes changing clinical trial design to allow in-
trasubject dose escalation, so an individual subject may
reach higher dosing without DLTs, or using a sequential
treatment paradigm [21]. Other options include using
alternative drug schedules, such as pulsatile dosing to
achieve better Central Nervous System (CNS) drug level
[24, 25] with the potential to limit exposure to prolonged
toxicities, as seen with the currently enrolling trial using
pulsatile dosing of erlotinib for recurrent GBM [26].
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